{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582393,"version":"4.4.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.1001\/jamadermatol.2022.1156","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T15:06:59Z","timestamp":1651676819000},"page":"641","source":"Crossref","is-referenced-by-count":44,"title":["Evaluation of Nomacopan for Treatment of Bullous Pemphigoid"],"prefix":"10.1001","volume":"158","author":[{"given":"Christian D.","family":"Sadik","sequence":"first","affiliation":[{"name":"Department of Dermatology, Allergy, and Venereology, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"Center for Research on Inflammation of the Skin, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Blistering Diseases, European Reference Network-Skin, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph M.","family":"Hammers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergy, and Venereology, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"Center for Research on Inflammation of the Skin, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles F.H.","family":"Diercks","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Blistering Diseases, European Reference Network-Skin, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"},{"name":"Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University of Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Center\u2013University of Freiburg, Faculty of Medicine, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fettiplace","sequence":"additional","affiliation":[{"name":"Akari Therapeutics Plc, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Center for Research on Inflammation of the Skin, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenting","family":"Ngai","sequence":"additional","affiliation":[{"name":"Akari Therapeutics Plc, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles A.","family":"Nunn","sequence":"additional","affiliation":[{"name":"Akari Therapeutics Plc, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergy, and Venereology, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"Center for Research on Inflammation of the Skin, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Blistering Diseases, European Reference Network-Skin, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi220018r1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jaci.2020.02.020","article-title":"Recent progresses and perspectives in autoimmune bullous diseases.","volume":"145","author":"Sadik","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"doi220018r2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid.","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"doi220018r3","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1053\/j.seminhematol.2016.04.015","article-title":"Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases.","volume":"53","author":"Sadik","year":"2016","journal-title":"Semin Hematol"},{"issue":"3","key":"doi220018r4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2340\/00015555-1925","article-title":"A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre.","volume":"95","author":"Kibsgaard","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi220018r5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/jdv.2014.28.issue-6","article-title":"Whole body application of a potent topical corticosteroid for bullous pemphigoid.","volume":"28","author":"Terra","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi220018r6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bjd.2013.169.issue-5","article-title":"The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi220018r7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi220018r8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"doi220018r9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid.","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol"},{"issue":"9","key":"doi220018r10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jde.2018.45.issue-9","article-title":"Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios.","volume":"45","author":"Kridin","year":"2018","journal-title":"J Dermatol"},{"key":"doi220018r11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fmed.2018.00238","article-title":"Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature.","volume":"5","author":"Bech","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"doi220018r12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2.","volume":"9","author":"Karsten","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"doi220018r13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc?RIIB and dectin-1.","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"doi220018r14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid.","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"doi220018r15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","article-title":"The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin.","volume":"37","author":"Sadik","year":"2018","journal-title":"Semin Immunol"},{"issue":"5","key":"doi220018r16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita.","volume":"137","author":"Sezin","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"15","key":"doi220018r17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128239","article-title":"Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.","volume":"4","author":"Sezin","year":"2019","journal-title":"JCI Insight"},{"issue":"11","key":"doi220018r18","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jid.2021.04.009","article-title":"Dapsone suppresses disease in preclinical murine models of pemphigoid diseases.","volume":"141","author":"Murthy","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"7","key":"doi220018r19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/archderm.1989.01670190059006","article-title":"Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid.","volume":"125","author":"Grando","year":"1989","journal-title":"Arch Dermatol"},{"issue":"4","key":"doi220018r20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2340\/0001555570281285","article-title":"Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions.","volume":"70","author":"Kawana","year":"1990","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"doi220018r21","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.4049\/jimmunol.1101000","article-title":"Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans.","volume":"187","author":"Barratt-Due","year":"2011","journal-title":"J Immunol"},{"issue":"11","key":"doi220018r22","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.1074\/jbc.M609858200","article-title":"In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata.","volume":"282","author":"Hepburn","year":"2007","journal-title":"J Biol Chem"},{"issue":"5","key":"doi220018r23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5.","volume":"23","author":"Jore","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"doi220018r24","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata.","volume":"174","author":"Nunn","year":"2005","journal-title":"J Immunol"},{"issue":"26","key":"doi220018r25","doi-asserted-by":"publisher","first-page":"18789","DOI":"10.1074\/jbc.M112.420331","article-title":"Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury.","volume":"288","author":"Roversi","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"doi220018r26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13023-021-01890-6","article-title":"Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results.","volume":"16","author":"S\u00e1nchez-Tabernero","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"doi220018r27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bjh.v188.2","article-title":"Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).","volume":"188","author":"Schols","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"doi220018r29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization Good Clinical Practice guideline.","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual Assur"},{"issue":"2","key":"doi220018r30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000362717","article-title":"Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients.","volume":"229","author":"L\u00e9vy-Sitbon","year":"2014","journal-title":"Dermatology"},{"issue":"6","key":"doi220018r31","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.v184.6","article-title":"International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220018r32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1017\/S1092852919001627","article-title":"Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder.","volume":"26","author":"Avasarala","year":"2021","journal-title":"CNS Spectr"},{"issue":"9665","key":"doi220018r33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria.","volume":"373","author":"Parker","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"doi220018r34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi220018r35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.2015.172.issue-4","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology.","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220018r36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"9863","key":"doi220018r37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases.","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"doi220018r38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"doi220018r39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.smim.2017.08.007","article-title":"Recent advances in clinical development of leukotriene B4 pathway drugs.","volume":"33","author":"Bhatt","year":"2017","journal-title":"Semin Immunol"},{"issue":"9","key":"doi220018r40","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis.","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"doi220018r41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/13543784.2018.1472234","article-title":"Avacopan in the treatment of ANCA-associated vasculitis.","volume":"27","author":"Tesar","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"doi220018r28","unstructured":"Nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteriod therapy (ARREST-BP). ClinicalTrials.gov indentifier: NCT05061771. Accessed March 29, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05061771"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2791461\/jamadermatology_sadik_2022_oi_220018_1654530027.60753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T01:26:06Z","timestamp":1700529966000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2791461"}},"subtitle":["A Phase 2a Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.1156","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}